NLS PHARMACEUTICS LTD. UNDERWRITING AGREEMENTUnderwriting Agreement • January 20th, 2021 • NLS Pharmaceutics Ltd. • Pharmaceutical preparations • New York
The undersigned, NLS Pharmaceutics Ltd., a corporation incorporated under the laws of Switzerland (the “Company”), hereby confirms its agreement (this “Agreement”) to issue and sell to the underwriter or underwriters, as the case may be, named in Schedule I hereto (each, an “Underwriter” and, collectively, the “Underwriters”), for whom Maxim Group LLC is acting as representative (in such capacity, the “Representative”), an aggregate of ________ units (the “Firm Units” or “Units”) of the Company’s securities, and, at the election of the Representative, up to an additional ________ Option Shares (as defined herein and collectively with the Common Shares (as defined below) underlying the Firm Units, the “Shares”), and/or up to an additional _________ Option Warrants (as defined herein and collectively with warrants underlying the Firm Units, the “Warrants”). Each Unit consists of one Common Share (the “Firm Shares”) of the Company, par value CHF 0.02 per share (the “Common Shares”) and on
Addendum Number 4 to the Convertible Loan Agreement of January 8, 2021 betweenNLS Pharmaceutics Ltd. • January 20th, 2021 • Pharmaceutical preparations
3rd Amendment to the Series A Loan Agreement of betweenNLS Pharmaceutics Ltd. • January 20th, 2021 • Pharmaceutical preparations
Addendum Number 4 of the “Up to USD 7,100,000 Credit Facilites Agreement” ofNLS Pharmaceutics Ltd. • January 20th, 2021 • Pharmaceutical preparations
Addendum Number 4 of the “Up to USD 150,000.00 Credit Facilites Agreement” ofNLS Pharmaceutics Ltd. • January 20th, 2021 • Pharmaceutical preparations
2nd Amendment to the Series A Loan Agreement of betweenNLS Pharmaceutics Ltd. • January 20th, 2021 • Pharmaceutical preparations
